Cargando…

The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins

Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fangfang, Liu, Ping, Huang, Yuyou, Li, Lingzhi, Zhang, Sijia, Yang, Zhenhong, Wang, Rongliang, Tao, Zhen, Han, Ziping, Fan, Junfen, Zheng, Yangmin, Zhao, Haiping, Luo, Yumin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371202/
https://www.ncbi.nlm.nih.gov/pubmed/34421795
http://dx.doi.org/10.3389/fneur.2021.691886
_version_ 1783739591737475072
author Li, Fangfang
Liu, Ping
Huang, Yuyou
Li, Lingzhi
Zhang, Sijia
Yang, Zhenhong
Wang, Rongliang
Tao, Zhen
Han, Ziping
Fan, Junfen
Zheng, Yangmin
Zhao, Haiping
Luo, Yumin
author_facet Li, Fangfang
Liu, Ping
Huang, Yuyou
Li, Lingzhi
Zhang, Sijia
Yang, Zhenhong
Wang, Rongliang
Tao, Zhen
Han, Ziping
Fan, Junfen
Zheng, Yangmin
Zhao, Haiping
Luo, Yumin
author_sort Li, Fangfang
collection PubMed
description Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory therapeutic strategies. Patients with first-ever AIS (n = 202) within 24 h were recruited. Plasma HGF and related interleukin concentrations were measured by multiplex immunoassays. The primary and secondary outcomes were major disability (modified Rankin scale score ≥3) at 3 months after AIS and death, respectively. Elastic net regression was applied to screen variables associated with stroke outcome; binary multivariable logistic analysis was then used to explore the relationship between HGF level and stroke outcome. After multivariate adjustment, upregulated HGF levels were associated with an increased risk of the primary outcome (odds ratio, 7.606; 95% confidence interval, 3.090–18.726; p < 0.001). Adding HGF to conventional risk factors significantly improved the predictive power for unfavorable outcomes (continuous net reclassification improvement 37.13%, p < 0.001; integrated discrimination improvement 8.71%, p < 0.001). The area under the receiver operating characteristic curve value of the traditional model was 0.8896 and reached 0.9210 when HGF was introduced into the model. An elevated HGF level may also be a risk factor for mortality within 3 months poststroke. The HGF level was also positively correlated with IL-10 and IL-16 levels, and HGF before interaction with all interleukins was markedly negatively correlated with the lymphocyte/neutrophil ratio. HGF within 24 h may have prognostic potential for AIS. Our findings reinforce the link between HGF and interleukins.
format Online
Article
Text
id pubmed-8371202
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83712022021-08-19 The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins Li, Fangfang Liu, Ping Huang, Yuyou Li, Lingzhi Zhang, Sijia Yang, Zhenhong Wang, Rongliang Tao, Zhen Han, Ziping Fan, Junfen Zheng, Yangmin Zhao, Haiping Luo, Yumin Front Neurol Neurology Hepatocyte growth factor (HGF) is a potential prognostic factor for acute ischemic stroke (AIS). In this study, we sought to validate its earlier predictive accuracy within 24 h for first-ever AIS. Moreover, as HGF interacts with interleukins, their associations may lead to novel immunomodulatory therapeutic strategies. Patients with first-ever AIS (n = 202) within 24 h were recruited. Plasma HGF and related interleukin concentrations were measured by multiplex immunoassays. The primary and secondary outcomes were major disability (modified Rankin scale score ≥3) at 3 months after AIS and death, respectively. Elastic net regression was applied to screen variables associated with stroke outcome; binary multivariable logistic analysis was then used to explore the relationship between HGF level and stroke outcome. After multivariate adjustment, upregulated HGF levels were associated with an increased risk of the primary outcome (odds ratio, 7.606; 95% confidence interval, 3.090–18.726; p < 0.001). Adding HGF to conventional risk factors significantly improved the predictive power for unfavorable outcomes (continuous net reclassification improvement 37.13%, p < 0.001; integrated discrimination improvement 8.71%, p < 0.001). The area under the receiver operating characteristic curve value of the traditional model was 0.8896 and reached 0.9210 when HGF was introduced into the model. An elevated HGF level may also be a risk factor for mortality within 3 months poststroke. The HGF level was also positively correlated with IL-10 and IL-16 levels, and HGF before interaction with all interleukins was markedly negatively correlated with the lymphocyte/neutrophil ratio. HGF within 24 h may have prognostic potential for AIS. Our findings reinforce the link between HGF and interleukins. Frontiers Media S.A. 2021-08-04 /pmc/articles/PMC8371202/ /pubmed/34421795 http://dx.doi.org/10.3389/fneur.2021.691886 Text en Copyright © 2021 Li, Liu, Huang, Li, Zhang, Yang, Wang, Tao, Han, Fan, Zheng, Zhao and Luo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Li, Fangfang
Liu, Ping
Huang, Yuyou
Li, Lingzhi
Zhang, Sijia
Yang, Zhenhong
Wang, Rongliang
Tao, Zhen
Han, Ziping
Fan, Junfen
Zheng, Yangmin
Zhao, Haiping
Luo, Yumin
The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title_full The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title_fullStr The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title_full_unstemmed The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title_short The Incremental Prognostic Value of Hepatocyte Growth Factor in First-Ever Acute Ischemic Stroke: An Early Link Between Growth Factor and Interleukins
title_sort incremental prognostic value of hepatocyte growth factor in first-ever acute ischemic stroke: an early link between growth factor and interleukins
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371202/
https://www.ncbi.nlm.nih.gov/pubmed/34421795
http://dx.doi.org/10.3389/fneur.2021.691886
work_keys_str_mv AT lifangfang theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT liuping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT huangyuyou theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT lilingzhi theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhangsijia theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT yangzhenhong theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT wangrongliang theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT taozhen theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT hanziping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT fanjunfen theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhengyangmin theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhaohaiping theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT luoyumin theincrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT lifangfang incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT liuping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT huangyuyou incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT lilingzhi incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhangsijia incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT yangzhenhong incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT wangrongliang incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT taozhen incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT hanziping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT fanjunfen incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhengyangmin incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT zhaohaiping incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins
AT luoyumin incrementalprognosticvalueofhepatocytegrowthfactorinfirsteveracuteischemicstrokeanearlylinkbetweengrowthfactorandinterleukins